CUE

insider transactions

Cue Biopharma, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Cluster buy signal: 2 different insiders made open-market purchases in the last 365 days, totalling $1.1M.

Net shares · 365d

+460.2K

460.2K buy · 0 sell

Net value · 365d

$1.1M

$1.1M in · $0 out

Sentiment · 365d

Net buying

100% buying · 0% selling

Open-market trades · 365d

460.2K buy · 0 sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Buy·P
Jun 1, 26

Shao-Lee Lin KEY

Chief Executive Officer

—

45.5K sh

Own New
Buy·P
Jun 1, 26

Shao-Lee Lin KEY

Chief Executive Officer

$1000.0K

90.9K sh · $11.00

Own New
Grant·A
May 30, 26

Viola Mong Meehan

Director

$0

1.6K sh

Own New
Grant·A
May 30, 26

Daniel A. Camardo

Director

$0

1.6K sh

Own New
Grant·A
May 3, 26

Shao-Lee Lin KEY

CHIEF EXECUTIVE OFFICER

$0

655.1K sh

Own New
Grant·A
May 3, 26

Shao-Lee Lin KEY

CHIEF EXECUTIVE OFFICER

$0

327.5K sh

Own New
Grant·A
Apr 9, 26

Colin Sandercock

SVP, GENERAL COUNSEL

$0

200.0K sh

Own New
Grant·A
Apr 9, 26

Lucinda Warren

CHIEF BUSINESS OFFICER

$0

250.0K sh

Own New
Grant·A
Jan 2, 26

Peter A Kiener

Director

$0

24.4K sh

Own New
Grant·A
Jan 2, 26

Frank Morich

Director

$0

24.4K sh

Own New
Grant·A
Jan 2, 26

Pamela Garzone

Director

$0

24.4K sh

Own New
Grant·A
Jan 2, 26

Patrick Verheyen

Director

$0

24.4K sh

Own New
Grant·A
Jan 2, 26

Pasha Sarraf

Director

$0

24.4K sh

Own New
Buy·P
Dec 30, 25

Pasha Sarraf

Director

$23.3K

77.4K sh · $0.30

Own +31%
Buy·P
Dec 30, 25

Pasha Sarraf

Director

$24.3K

78.1K sh · $0.31

Own +46%
Buy·P
Dec 30, 25

Pasha Sarraf

Director

$27.6K

86.9K sh · $0.32

Own +107%
Buy·P
Dec 30, 25

Pasha Sarraf

Director

$23.2K

77.1K sh · $0.30

Own +1824%
Buy·P
Dec 30, 25

Pasha Sarraf

Director

$1.3K

4.2K sh · $0.31

Own New

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 1, 2026	Shao-Lee Lin KEY	Chief Executive Officer	Buy P	45.5K	New	—	—
Jun 1, 2026	Shao-Lee Lin KEY	Chief Executive Officer	Buy P	90.9K	New	$11.00	$1000.0K
May 30, 2026	Viola Mong Meehan	Director	Grant A	1.6K	New	—	$0
May 30, 2026	Daniel A. Camardo	Director	Grant A	1.6K	New	—	$0
May 3, 2026	Shao-Lee Lin KEY	CHIEF EXECUTIVE OFFICER	Grant A	655.1K	New	—	$0
May 3, 2026	Shao-Lee Lin KEY	CHIEF EXECUTIVE OFFICER	Grant A	327.5K	New	—	$0
Apr 9, 2026	Colin Sandercock	SVP, GENERAL COUNSEL	Grant A	200.0K	New	—	$0
Apr 9, 2026	Lucinda Warren	CHIEF BUSINESS OFFICER	Grant A	250.0K	New	—	$0
Jan 2, 2026	Peter A Kiener	Director	Grant A	24.4K	New	—	$0
Jan 2, 2026	Frank Morich	Director	Grant A	24.4K	New	—	$0
Jan 2, 2026	Pamela Garzone	Director	Grant A	24.4K	New	—	$0
Jan 2, 2026	Patrick Verheyen	Director	Grant A	24.4K	New	—	$0
Jan 2, 2026	Pasha Sarraf	Director	Grant A	24.4K	New	—	$0
Dec 30, 2025	Pasha Sarraf	Director	Buy P	77.4K	+31%	$0.30	$23.3K
Dec 30, 2025	Pasha Sarraf	Director	Buy P	78.1K	+46%	$0.31	$24.3K
Dec 30, 2025	Pasha Sarraf	Director	Buy P	86.9K	+107%	$0.32	$27.6K
Dec 30, 2025	Pasha Sarraf	Director	Buy P	77.1K	+1824%	$0.30	$23.2K
Dec 30, 2025	Pasha Sarraf	Director	Buy P	4.2K	New	$0.31	$1.3K

About CUE insider trading

This page tracks insider transactions for Cue Biopharma, Inc. (CUE) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.